Tvardi Therapeutics
TVRD
137 hedge funds and large institutions have $83.3M invested in Tvardi Therapeutics in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 37 reducing their positions, and 46 closing their positions.
784% more call options, than puts
Call options by funds: $327K | Put options by funds: $37K
27% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 37
0.23% less ownership
Funds ownership: 1.75% → 1.51% (-0.23%)
16% less funds holding
Funds holding: 163 → 137 (-26)
50% less capital invested
Capital invested by funds: $166M → $83.3M (-$83.1M)
54% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.91M |
| 2 |
Millennium Management
New York
|
+$2.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.39M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.25M |
| 5 |
ClearBridge Investments
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$14.9M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$6.05M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$4.86M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.76M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.08M |
TVRD Hedge Fund Activity: Q2 2023 in Review
137 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2023, worth a combined $83.3M — down 50% from $166M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of TVRD and 21 opened new positions — a net loss of 25 holders — while 37 trimmed existing stakes and 47 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $3.91M. The largest seller was BlackRock, cutting an estimated $14.9M.
- 137 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2023, down from 163 in Q1 2023.
- Funds reported $83.3M of Tvardi Therapeutics stock for Q2 2023, down 50% quarter-over-quarter.
- 21 funds opened new Tvardi Therapeutics positions in Q2 2023 and 46 closed out, a net change of -25 holders.
- The largest Tvardi Therapeutics buyer in Q2 2023 was Jacobs Levy Equity Management, an estimated $3.91M added.
- The largest Tvardi Therapeutics seller in Q2 2023 was BlackRock, an estimated $14.9M sold.
Based on aggregated 13F filings for Q2 2023.